Drug
Emraclidine clinical trials
Also written CVL-231 and ABBV-1231.
- studies test it
- 17
- open now
- 2
- in phase 3
- 0
- first study started
- 2017
Keep track of what changes. Save the emraclidine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- CVL-231
- 12
Studies by the year they started
17 studies that test it; most in 2022 (5)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 5 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 13
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses emraclidine is read from its arms, and is right about nine times in ten.
Testing it · 17
- A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With SchizophreniaRecruitingPhase 2AbbVieNCT07145918Written as Emraclidine
- A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult ParticipantsRecruitingPhase 1AbbVieNCT07219030Written as Emraclidine
- A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With SchizophreniaTerminatedPhase 2AbbVieNCT05443724Written as Emraclidine 30 mg
- Study to Assess Adverse Events and How Oral Emraclidine Moves Through the Body of Adult Healthy VolunteersCompletedPhase 1AbbVieNCT07587008Written as Emraclidine
- A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With SchizophreniaCompletedPhase 2AbbVieNCT05227703Written as Emraclidine 15 mg
- A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With SchizophreniaCompletedPhase 2AbbVieNCT05227690Written as Emraclidine 10 mg
- A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's DiseaseCompletedPhase 1AbbVieNCT05644977Written as Emraclidine
- A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal FunctionCompletedPhase 1AbbVieNCT05940402Written as Emraclidine
- A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of EmraclidineCompletedPhase 1AbbVieNCT05935033Written as Emraclidine
- A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult ParticipantsCompletedPhase 1Cerevel Therapeutics, LLCNCT06366243Written as Emraclidine
- A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male ParticipantsCompletedPhase 1Cerevel Therapeutics, LLCNCT06301971Written as Emraclidine
- The Effect of Food on the Pharmacokinetics (PK) of Emraclidine in Healthy Adult ParticipantsCompletedPhase 1Cerevel Therapeutics, LLCNCT05915546Written as Emraclidine
- A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult ParticipantsCompletedPhase 1Cerevel Therapeutics, LLCNCT05933187Written as Treatment A: Emraclidine 30mg IR tablets (reference)
- PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral DosingCompletedPhase 1Cerevel Therapeutics, LLCNCT04787302Written as CVL-231
- Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With SchizophreniaCompletedPhase 1Cerevel Therapeutics, LLCNCT05245539Written as CVL-231
- A Multiple Ascending Dose Trial of CVL-231 in Subjects With SchizophreniaCompletedPhase 1Cerevel Therapeutics, LLCNCT04136873Written as CVL-231
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of PF-06852231 in Healthy SubjectsCompletedPhase 1PfizerNCT03217604Written as PF-06852231
Given in every arm · 1 — emraclidine is usual care beside what is tested
Codes
What other systems call emraclidine · ClinicalTrials.gg INT016894
- UNII (FDA) J241Y80EEOEMRACLIDINEConfirmed FDA, Wikidata
- Wikidata Q116786342emraclidineConfirmed FDA, Wikidata
- NCI Thesaurus C184922EmraclidineOne source FDA
- DrugBank DB18706One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | J241Y80EEO | EMRACLIDINE | Confirmed FDA, Wikidata |
| Wikidata | Q116786342 | emraclidine | Confirmed FDA, Wikidata |
| NCI Thesaurus | C184922 | Emraclidine | One source FDA |
| DrugBank | DB18706 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.